Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Molecular Biology of Phosphodiesterase 4 Enzymes as Pharmacological Targets: An Interplay of Isoforms, Conformational States, and Inhibitors
Dean Paes, Melissa Schepers, Ben Rombaut, et al.
Pharmacological Reviews (2021) Vol. 73, Iss. 3, pp. 1016-1049
Open Access | Times Cited: 67

Showing 1-25 of 67 citing articles:

An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022
Letizia Crocetti, Giuseppe Floresta, Agostino Cilibrizzi, et al.
Molecules (2022) Vol. 27, Iss. 15, pp. 4964-4964
Open Access | Times Cited: 74
cAMP-PKA/EPAC signaling and cancer: the interplay in tumor microenvironment
Hongying Zhang, Yongliang Liu, Jieya Liu, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 32
Connecting dots: Preclinical foundations to clinical realities of PDE4 inhibitors in Alzheimer's disease
Shilpa Kumari, Kajal Bagri, Rahul Deshmukh
Inflammopharmacology (2025)
Closed Access | Times Cited: 2
Selective PDE4 subtype inhibition provides new opportunities to intervene in neuroinflammatory versus myelin damaging hallmarks of multiple sclerosis
Melissa Schepers, Dean Paes, Assia Tiane, et al.
Brain Behavior and Immunity (2022) Vol. 109, pp. 1-22
Open Access | Times Cited: 39
Exploring the Therapeutic Landscape: A Narrative Review on Topical and Oral Phosphodiesterase-4 Inhibitors in Dermatology
Elena Carmona‐Rocha, Lluís Rusiñol, L. Puig
Pharmaceutics (2025) Vol. 17, Iss. 1, pp. 91-91
Open Access | Times Cited: 1
Advances in pyrazolo[1,5-a]pyrimidines: synthesis and their role as protein kinase inhibitors in cancer treatment
Terungwa H. Iorkula, Osasere Jude-Kelly Osayawe, Daniel A. Odogwu, et al.
RSC Advances (2025) Vol. 15, Iss. 5, pp. 3756-3828
Open Access | Times Cited: 1
Ablation of specific long PDE4D isoforms increases neurite elongation and conveys protection against amyloid-β pathology
Dean Paes, Melissa Schepers, Emily Willems, et al.
Cellular and Molecular Life Sciences (2023) Vol. 80, Iss. 7
Open Access | Times Cited: 18
Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review
Andrew Blauvelt, Richard Langley, Kenneth B. Gordon, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 12, pp. 3031-3042
Open Access | Times Cited: 17
Artesunate inhibits PDE4 leading to intracellular cAMP accumulation, reduced ERK/MAPK signaling, and blockade of influenza A virus vRNP nuclear export
Xia Yang, Feixiang Long, Weixin Jia, et al.
Antiviral Research (2023) Vol. 215, pp. 105635-105635
Open Access | Times Cited: 16
GNAS mutation inhibits growth and induces phosphodiesterase 4D expression in colorectal cancer cell lines
Pirjo Nummela, Sadia Zafar, Erika Veikkolainen, et al.
International Journal of Cancer (2024) Vol. 154, Iss. 11, pp. 1987-1998
Open Access | Times Cited: 7
PDE4 inhibitors: potential protective effects in inflammation and vascular diseases
Tianfei Fan, Wenjing Wang, Yao Wang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 7
Beyond PDE4 inhibition: A comprehensive review on downstream cAMP signaling in the central nervous system
Zoë Donders, Iga Joanna Skorupska, Emily Willems, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 177, pp. 117009-117009
Open Access | Times Cited: 7
The potential therapeutic effect of phosphodiesterase 5 inhibitors in the acute ischemic stroke (AIS)
Raed AlRuwaili, Hayder M. Al‐kuraishy, Mubarak Alruwaili, et al.
Molecular and Cellular Biochemistry (2023) Vol. 479, Iss. 5, pp. 1267-1278
Open Access | Times Cited: 15
Structure-based method for the discovery of selective inhibitors of PED 5 in erectile dysfunction therapy from the Pacific oyster peptides (Crassostrea gigas): Peptidomic analysis, molecular docking, and activity validation
Jianhui Feng, Wenhao Cao, Bo Xu, et al.
International Journal of Biological Macromolecules (2025) Vol. 295, pp. 139494-139494
Closed Access
Phosphodiesterase 4D inhibition improves the functional and molecular outcome in a mouse and human model of Charcot Marie Tooth disease 1 A
Melissa Schepers, Tim Vangansewinkel, Karen Libberecht, et al.
Biomedicine & Pharmacotherapy (2025) Vol. 183, pp. 117828-117828
Open Access
A PDE4 shortform degrader: a first in isoform‐specific PDE4 inhibition
Donald H. Maurice
FEBS Journal (2025)
Open Access
The multifaceted role of phosphodiesterase 4 in tumor: from tumorigenesis to immunotherapy
Huimin Ren, Shaohui Zhang, Peiyuan Li
Frontiers in Immunology (2025) Vol. 16
Open Access
Structure-Based Optimization of Moracin M as Potent and Selective PDE4 Inhibitors with Antipsoriasis Effects
Furong Zhang, Tiansheng Zheng, Xue Wang, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Microglial circDlg1 modulates neuroinflammation by blocking PDE4B ubiquitination-dependent degradation associated with Alzheimer's disease
Jiyun Shi, Chenghuan Song, Pingao Zhang, et al.
Theranostics (2025) Vol. 15, Iss. 8, pp. 3401-3423
Open Access
Neuroprotective Effects of Cilomilast and Chlorogenic Acid Against Scopolamine-Induced Memory Deficits via Modulation of the cAMP/PKA–CREB–BDNF Pathway
Esraa M. Mosalam, Soha Mohamed Atya, Noha M. Mesbah, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 7, pp. 3108-3108
Open Access
Neuroinflammation in Ischemic Stroke: Inhibition of cAMP-Specific Phosphodiesterases (PDEs) to the Rescue
Laura Ponsaerts, Lotte Alders, Melissa Schepers, et al.
Biomedicines (2021) Vol. 9, Iss. 7, pp. 703-703
Open Access | Times Cited: 29
Phosphodiesterase‑4 inhibitors: a review of current developments (2013–2021)
Zhihao Liu, Mingjian Liu, Zhenqing Cao, et al.
Expert Opinion on Therapeutic Patents (2022) Vol. 32, Iss. 3, pp. 261-278
Closed Access | Times Cited: 21
Moderate-Intensity Intermittent Training Alters the DNA Methylation Pattern of PDE4D Gene in Hippocampus to Improve the Ability of Spatial Learning and Memory in Aging Rats Reduced by D-Galactose
Jinmei Zhang, Qiao-Jing Gao, Jun Gao, et al.
Brain Sciences (2023) Vol. 13, Iss. 3, pp. 422-422
Open Access | Times Cited: 12
PDE4 Inhibitors: Profiling Hits through the Multitude of Structural Classes
Jin Jian, Francesca Mazzacuva, Letizia Crocetti, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11518-11518
Open Access | Times Cited: 12
Phosphodiesterase-4 Inhibition in Parkinson’s Disease: Molecular Insights and Therapeutic Potential
Dhritiman Roy, Shivaramakrishnan Balasubramanian, Praveen Thaggikuppe Krishnamurthy, et al.
Cellular and Molecular Neurobiology (2023) Vol. 43, Iss. 6, pp. 2713-2741
Closed Access | Times Cited: 11
Page 1 - Next Page

Scroll to top